Clinical Trial Update: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks [Phase 3]

View source ↗

Summary

This Phase 3 trial update compares denosumab given every 4 weeks versus every 12 weeks for prevention of symptomatic skeletal events in patients with metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer
• Prostate Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Metastatic Breast Cancer, Metastatic Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING